Literature DB >> 24434574

Combination of adenoviruses expressing melanoma differentiation-associated gene-7 and chemotherapeutic agents produces enhanced cytotoxicity on esophageal carcinoma.

G Ma1, K Kawamura2, Y Shan3, S Okamoto4, Q Li3, M Namba5, M Shingyoji6, Y Tada7, K Tatsumi7, K Hiroshima8, H Shimada9, M Tagawa3.   

Abstract

We examined the combinatory antitumor effects of adenoviruses expressing human mda-7/IL-24 gene (Ad-mda-7) and chemotherapeutic agents on nine kinds of human esophageal carcinoma cells. All the carcinoma cells expressed the melanoma differentiation-associated gene-7/interleukin-24 (MDA-7/IL-24) receptor complexes, IL-20R2 and either IL-20R1 or IL-22R1, and were susceptible to Ad-mda-7, whereas fibroblasts were positive only for IL-20R2 gene and resistant to Ad-mda-7-mediated cytotoxicity. Sensitivity of these esophageal carcinoma cells to Ad-mda-7 was however lower than that to Ad expressing the wild-type p53 gene. We thereby investigated a possible combination of Ad-mda-7 and anticancer agents and found that Ad-mda-7 with 5-fluorouracil (5-FU), cisplatin, mitomycin C or etoposide produced greater cytotoxic effects than those by Ad-mda-7 or the agent alone. Half-maximal inhibitory concentration values of the agents in respective cells were decreased by the combination with Ad-mda-7. Cell cycle analyses showed that Ad-mda-7 and 5-FU increased G2/M-phase and S-phase populations, respectively, and the combination augmented sub-G1 populations. Ad-mda-7-treated cells showed cleavages of caspase-8, -9 and -3 and poly (ADP-ribose) polymerase, but the cleavage levels were not different from those of the combination-treated cells. Ad-mda-7 treatments upregulated Akt phosphorylation but suppressed IκB-α levels, whereas 5-FU treatments induced phosphorylation of p53 and extracellular signal-regulated protein kinases 1 and 2. Molecular changes caused by the combination were similar to those by Ad-mda-7 treatments, but the Ad-mda-7-mediated upregulation of Akt phosphorylation decreased with the combination. These data collectively suggest that Ad-mda-7 induced apoptosis despite Akt activation and that the combinatory antitumor effects with 5-FU were produced partly by downregulating the Ad-mda-7-induced Akt activation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24434574     DOI: 10.1038/cgt.2013.79

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  24 in total

1.  Phase I/II adenoviral p53 gene therapy for chemoradiation resistant advanced esophageal squamous cell carcinoma.

Authors:  Hideaki Shimada; Hisahiro Matsubara; Tooru Shiratori; Takanori Shimizu; Shinichi Miyazaki; Shinichi Okazumi; Yoshihiro Nabeya; Kiyohiko Shuto; Hideki Hayashi; Tooru Tanizawa; Yukio Nakatani; Hiromitsu Nakasa; Mitsukazu Kitada; Takenori Ochiai
Journal:  Cancer Sci       Date:  2006-06       Impact factor: 6.716

2.  Enhancement of adenoviral MDA-7-mediated cell killing in human lung cancer cells by geldanamycin and its 17-allyl- amino-17-demethoxy analogue.

Authors:  A Pataer; D Bocangel; S Chada; J A Roth; K K Hunt; S G Swisher
Journal:  Cancer Gene Ther       Date:  2006-10-06       Impact factor: 5.987

Review 3.  MDA-7/IL-24 as a cancer therapeutic: from bench to bedside.

Authors:  Paul Dent; Adly Yacoub; Hossein A Hamed; Margaret A Park; Rupesh Dash; Sujit K Bhutia; Devanand Sarkar; Pankaj Gupta; Luni Emdad; Irina V Lebedeva; Moira Sauane; Zhao-Zhong Su; Mohamed Rahmani; William C Broaddus; Harold F Young; Maciej Lesniak; Steven Grant; David T Curiel; Paul B Fisher
Journal:  Anticancer Drugs       Date:  2010-09       Impact factor: 2.248

4.  Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study.

Authors:  C Casey Cunningham; Sunil Chada; James A Merritt; Alex Tong; Neil Senzer; Yuan Zhang; Abner Mhashilkar; Karen Parker; Sasha Vukelja; Don Richards; Jill Hood; Keith Coffee; John Nemunaitis
Journal:  Mol Ther       Date:  2005-01       Impact factor: 11.454

5.  Interleukin 24 (MDA-7/MOB-5) signals through two heterodimeric receptors, IL-22R1/IL-20R2 and IL-20R1/IL-20R2.

Authors:  Mai Wang; Zhongjia Tan; Rong Zhang; Sergei V Kotenko; Peng Liang
Journal:  J Biol Chem       Date:  2001-11-12       Impact factor: 5.157

Review 6.  Historical perspective and recent insights into our understanding of the molecular and biochemical basis of the antitumor properties of mda-7/IL-24.

Authors:  Luni Emdad; Irina V Lebedeva; Zhao-zhong Su; Pankaj Gupta; Moira Sauane; Rupesh Dash; Steven Grant; Paul Dent; David T Curiel; Devanand Sarkar; Paul B Fisher
Journal:  Cancer Biol Ther       Date:  2009-03-08       Impact factor: 4.742

7.  Cytotoxicity of adenoviruses expressing the wild-type p53 gene to esophageal carcinoma cells is linked with the CAR expression level and indirectly with the endogenous p53 status.

Authors:  G Ma; K Kawamura; Q Li; N Suzuki; M Liang; M Namba; H Shimada; M Tagawa
Journal:  Cancer Gene Ther       Date:  2009-04-10       Impact factor: 5.987

8.  Adenoviral endoplasmic reticulum-targeted mda-7/interleukin-24 vector enhances human cancer cell killing.

Authors:  Abujiang Pataer; Wenxian Hu; Lu Xiaolin; Sunil Chada; Jack A Roth; Kelly K Hunt; Stephen G Swisher
Journal:  Mol Cancer Ther       Date:  2008-08       Impact factor: 6.261

9.  Enhanced therapeutic efficacy of adenovirus-mediated interleukin-24 gene therapy combined with ionizing radiotherapy for nasopharyngeal carcinoma.

Authors:  Jisheng Liu; Yujuan Zhang; Peng Sun; Yufeng Xie; Jim Xiang; Jicheng Yang
Journal:  Oncol Rep       Date:  2013-06-19       Impact factor: 3.906

10.  Recombinant interleukin-24 lacks apoptosis-inducing properties in melanoma cells.

Authors:  Stephanie Kreis; Demetra Philippidou; Christiane Margue; Catherine Rolvering; Claude Haan; Laure Dumoutier; Jean-Christophe Renauld; Iris Behrmann
Journal:  PLoS One       Date:  2007-12-12       Impact factor: 3.240

View more
  5 in total

Review 1.  Role of MDA-7/IL-24 a Multifunction Protein in Human Diseases.

Authors:  Mitchell E Menezes; Praveen Bhoopathi; Anjan K Pradhan; Luni Emdad; Swadesh K Das; Chunqing Guo; Xiang-Yang Wang; Devanand Sarkar; Paul B Fisher
Journal:  Adv Cancer Res       Date:  2018-03-02       Impact factor: 6.242

Review 2.  Evolving Role of Oncolytic Virotherapy: Challenges and Prospects in Clinical Practice.

Authors:  Omeed Moaven; Christopher W Mangieri; John A Stauffer; Panos Z Anastasiadis; Mitesh J Borad
Journal:  JCO Precis Oncol       Date:  2021-02-24

3.  Targeted silencing of SOX2 by an artificial transcription factor showed antitumor effect in lung and esophageal squamous cell carcinoma.

Authors:  Etsuko Yokota; Tomoki Yamatsuji; Munenori Takaoka; Minoru Haisa; Nagio Takigawa; Noriko Miyake; Tomoko Ikeda; Tomoaki Mori; Serika Ohno; Takashi Sera; Takuya Fukazawa; Yoshio Naomoto
Journal:  Oncotarget       Date:  2017-10-05

4.  Identification of IL20RB as a Novel Prognostic and Therapeutic Biomarker in Clear Cell Renal Cell Carcinoma.

Authors:  Hongda Guo; Songlin Jiang; Haoyu Sun; Benkang Shi; Yan Li; Nan Zhou; Dongqing Zhang; Hu Guo
Journal:  Dis Markers       Date:  2022-03-08       Impact factor: 3.434

5.  Melanoma differentiation-associated gene-7 suppresses human gastric cancer cell invasion and migration.

Authors:  Li Xu; Jinyan Chen; Wei Lin; Jinkun Chen; Zhiwei Chen
Journal:  Oncol Lett       Date:  2017-09-27       Impact factor: 2.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.